Physicianscientists from NewYorkPresbyterian Hospital/Weill Cornell Medical Center believe that a heightened level a certain growth factor in the blood may explain why blacks have a greater prevalence of hypertension and kidney disease compared to whites. Results from a new study are the first to show that an elevated level of a protein, called transforming growth factor b1 (TGFb1), raises the risk of hypertension and renal disease in humans.

African Americans constitute about 32 percent of all patients treated for kidney failure in the U.S. and are four times more likely to develop renal disease than whites, according to the National Institutes of Healths U.S. Renal Data System. The researchers findings, published in this months issue of the journal Kidney International, may someday lead to the development of a new class of antihypertensive and kidney disease drugs that target the TGFb1 protein.

“I believe we may now understand a great puzzle why the black population has a greater prevalence of hypertension and kidney disease,” says Dr. Manikkam Suthanthiran, first author of the study and attending physician at NewYorkPresbyterian/Weill Cornell, Stanton Griffis Distinguished Professor of Medicine, Professor of Biochemistry and Professor of Medicine in Surgery at Weill Cornell Medical College.

Results from the study revealed that the TGFb1 protein was significantly higher in 186 black study participants compared with 147 white participants.

After controlling for race, sex and age, TGFb1 protein levels were highest in hypertensive blacks (46 ng/ml). Nonhypertensive blacks also had higher levels (42 ng/ml) compared to hypertensive whites (40 ng/ml) and nonhypertensive whites (39 ng/ml), demonstrating that even healthy black patients may be at higher risk for future hypertension and renal disease compared to healthy and hypertensive whites.

“Many black patients may have a disadvantage from the start having a higher baseline level of TGFb1,” says Dr. Phyllis August, senior author and attending physician in the division of hypertension at NewYorkPresbyterian Hospital/Weill Cornell Medical Center, Ralph A. Baer Professor of Medical Research and professor of medicine atWeill Cornell Medical College.

While the exact mechanisms of TGFb1 require further study, the authors believe that in black patients, higher levels of the growth factor are correlated with lower renin activity an enzyme that constricts blood vessels and raises blood pressure. High blood pressure is the leading risk factor for endstage kidney disease.

The authors believe it may be possible that higher levels of TGFb1 boost retention of sodium salt within the kidneys, leading to higher blood pressure in the kidney and also lower levels of renin.

Greater levels of TGFb1 in blacks were also positively associated with body mass index (BMI) indicator of body fatness compared to height and metabolic syndrome a group of abnormalities that is associated with atherosclerotic vascular disease and diabetes.

“Future clinical studies must be done so we may fully understand the specific role of TGFb1 in how the kidney handles sodium, blood pressure and kidney disease.” Says Dr. August.

Kidney injury that can arise after undergoing certain medical imaging procedures increases a patients risk of having a stroke or heart attack over the next year or two, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that seemingly minor and reversible kidney damage from these common clinical procedures is a serious health threat.

Medical imaging often uses contrast agents, substances such as iodine and barium that enhance the contrast of structures or fluids within the body. For example, contrast agents may be used during cardiac angiography and computed tomography procedures to visualize blood vessels and changes in tissues. Exposure to contrast agents can injure the kidneys, but patients are often told that this is only a temporary side effect. Recent research has suggested that such contrastinduced kidney damage may actually be more serious, although no thorough studies have looked into the hypothesis.

To investigate the issue, Richard Solomon, MD (University of Vermont), and his colleagues studied 294 patients with kidney disease who were exposed to contrast agents during cardiac angiography. Patients in the CARE (Cardiac Angiography in REnally Impaired Patients) trial were randomly divided to receive one of two contrast agents iopamidol or iodixanol. After following patients for at least one year, the researchers found that 92 (31%) of the patients experienced negative health effects. Thirtyeight (13%) of the patients experienced a major event, such as death, stroke, heart attack, or endstage renal disease. Individuals who developed contrastinduced kidney injuries had twice as many longterm negative health effects compared with patients whose kidneys were not damaged. In the absence of contrastinduced kidney injury, there was no difference in the incidence of longterm negative health effects between patients taking iopamidol or iodixanol. However, the investigators found that patients taking iopamidol had reduced incidences of both kidney damage and longterm negative effects. These parallel decreased incidences support the theory that contrastinduced kidney injury causes longterm negative effects.

The CARE trial findings should prompt investigators to design additional studies on the longterm negative health effects of contrastinduced kidney damage.

This work was supported by Bracco Diagnostics, Inc., which manufactures iopamidol. Dr. Solomon serves as a consultant for Bracco Diagnostics, Inc. Study coauthors who received research funding from Bracco Diagnostics, Inc. include Madhu Natarajan, MD (Hamilton Health Sciences, Canada), Serge Doucet, MD (Montreal Heart Institute, Canada), Richard Katholi, MD (Prairie Educational and Research Cooperative), Cezar Staniloae, MD (St. Vincents Hospital Manhattan and Medical Center), Samin Sharma, MD (Mt. Sinai Medical Center), Marino Labinaz, MD (University of Ottawa Heart Institute, Canada), and Joseph Gelormini, MD (Buffalo Heart Group). Coauthors Roxana Mehran, MD (New YorkPresbyterian Hospital/Columbia University Medical Center) and Brendan Barrett, MD (Memorial University of Newfoundland, Canada) report no financial disclosures.

Founded in 1966, the American Society of Nephrology (ASN) is the worlds largest professional society devoted to the study of kidney disease. Comprised of 11,000 physicians and scientists, ASN continues to promote expert patient care, to advance medical research, and to educate the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients. ASN funds research, and through its worldrenowned meetings and firstclass publications, disseminates information and educational tools that empower physicians.

Early results from a Mayo Clinic research study demonstrate the effectiveness of a new approach to blocking an important part of the immune system that causes severe damage to some kidney transplants. Historically, these patients have been very difficult to treat successfully because their immune systems are already primed with antibodies to destroy the donor organ. These findings were presented at the American Transplant Congress.

Results show that the drug under study, called eculizumab, prevents antibodymediated kidney transplant rejection by inhibiting the immune systems activation of one of the bodys important defense mechanisms the complement system. Antibodymediated rejection is a major barrier to transplant in patients with antibodies against their living donors sometimes called “positive crossmatch kidney transplants.”

Though the results are preliminary and the study is ongoing, Mayo Clinics lead author, Mark Stegall, M.D., said the data suggest that eculizumab therapy may be a turning point for this select group of high risk kidney transplantation patients. “This innovative approach has the potential to make this type of high risk transplant possible for more people while improving outcomes,” he says

Background

Positive crossmatch patients have antibodies in their blood against foreign “tissue types” that are present on donor kidneys. These tissue types, termed Human Leukocyte Antigens (HLA), are the reason the transplant patients body perceives the donated kidney as “nonself” tissue. These antibodies result from previous transplants, blood transfusions or pregnancies.

Increasingly recognized as a major problem, high levels of these antibodies delay transplantation, as evidenced by the approximately 7,000 people on the United Network for Organ Sharing (UNOS) kidney waiting list who are still looking for a match. Mayo Clinic has long been a leader in devising innovative approaches to help this challenging group of kidney patients, and these latest findings about eculizumab add to the expertise and options offered to patients.

Significance of the Mayo Clinic research

This work suggests a novel way to block antibodymediated tissue injury. The Mayo team showed that eculizumab blocks the part of the immune system known as the complement system, which initiates tissue destruction. In this study, 10 positive crossmatch kidney transplant patients were treated with eculizumab. None of the treated patients developed antibodymediated rejection compared to historical controls in which 60 percent with similar levels of antibody would have developed antibodymediated rejection.

“These results are great news because they mean that none of the treated patients developed the most serious complication that normally threatens the transplant. This represents a quantum leap in this area,” explains Dr. Stegall.

Research rationale

High levels of antibodies were once considered an absolute contraindication to kidney transplantation; however, Mayo Clinic researchers and other groups have developed new protocols to successfully overcome antibody barriers mostly in the setting of living donation. Without such protocols, most of these patients would die without ever receiving a kidney transplant. Despite their general success, these protocols, which have been in use for almost a decade, have been complicated by a high rate of antibodymediated damage which can lead to early graft injury that shortens the lifespan of the transplant. Preventing antibodymediated rejection has been difficult. This new therapy may be a first step toward improved outcomes in these highrisk recipients.

Endothelial involvement

In addition to the 10sample study in which tissue destruction was prevented in all patients, the Mayo team presented a related, more detailed analysis of the ability of eculizumab to prevent kidney damage at the microscopic level. This study involved 62 tissue biopsies from 50 kidney transplant patients. The biopsies were analyzed using the electron microscope for evidence of the mechanism and process of tissue destruction.

Results showed that when acute antibodymediated rejection occurs, it involves changes observable by electron microscope in the endothelial cells lining the kidney blood vessels. These changes correspond with high levels of antibodies against the donor circulating in the patients blood serum. And importantly, by blocking a specific part of the immune system with eculizumab, doctors prevented endothelial activation. These results suggest the endothelial lining may be a potential target for developing new drugs to stop antibodymediated tissue destruction so that more positive crossmatch patients can be successfully transplanted. More research is needed to confirm these findings.

Collaboration

The Mayo Clinic research team also included Tayyab Diwan, M.D.; Justin Burns, M.D.; Patrick Dean, M.D.; Lynn Cornell, M.D.; Manish Gandhi, M.D.; Fernando Cosio, M.D.; and James Gloor, M.D.

This research was funded by Alexion Pharmaceuticals, Inc.

Source
Traci Klein

Omeros Corporation announced favorable results from a Phase 1 wheelscontrolled study of OMS201, another of Omeros PharmacoSurgery(TM) product candidates, for use as urological surgery.

The Phase 1 study of OMS201 enrolled patients undergoing endoscopic removal of urinary stones, and was designed to evaluate the systemic absorption and safety of the drug product. The pharmacokinetic dope from that study Showing that systemic plasma levels of the active agents of OMS201 in patients were minimal and in lions share cases below the like of quantification. There were no serious adverse events.

“We perdure to be encouraged by the progress being made in our OMS201 development program, and the completion of that study represents another bestselling milestone as we advance our PharmacoSurgery(TM) platform,” stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. “Based on these positive results, we hope to to initiate a Phase 1/Phase 2 study evaluating the safety and preliminary efficacy of two higher concentrations of OMS201 in uroendoscopic surgery.”

The Phase 1 study was a randomized, doubleblind, wheelscontrolled and parallelassigned study designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros proprietary PharmacoSurgeryTM platform, is designed for use midst urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added to classic irrigation solutions in urological surgery, OMS201 is delivered until the operation directly to the surgical slot to inhibit surgically induced inflammation, pain and smooth muscle spasm.

About Omeros Corporation

Omeros Corporation is a clinicalstage biopharmaceutical club committed to discovering, developing and commercializing outcomes focused on inflammation and disorders of the central nervous complex. Omeros largest clinically old product candidates are derived from its proprietary PharmacoSurgeryTM platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgeryTM clinical development programs, and its pilot product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use while arthroscopic surgery to improve postoperative joint task and reduce postoperative pain. Omeros is plus architecture a diverse pipeline of preclinical programs targeting inflammation and central nervous utilidor disorders. For more intelligence on Omeros, explore the zoos Web plot at omeros.com.

Omeros Corporation
omeros.com

Omeros Corporation announced favorable results from a Phase 1 boatcontrolled study of OMS201, another of Omeros PharmacoSurgery(TM) product candidates, for use meanwhile urological surgery.

The Phase 1 study of OMS201 enrolled patients undergoing endoscopic removal of urinary stones, and was designed to evaluate the systemic absorption and safety of the drug product. The pharmacokinetic testimony from that study exposition that systemic plasma levels of the active agents of OMS201 in patients were minimal and in maximum cases below the stable of quantification. There were no serious adverse events.

“We lengthen to be encouraged by the progress being made in our OMS201 development program, and the completion of that study represents another lucrative milestone as we advance our PharmacoSurgery(TM) platform,” stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. “Based on these positive results, we plot to initiate a Phase 1/Phase 2 study evaluating the safety and preliminary efficacy of two higher concentrations of OMS201 in uroendoscopic surgery.”

The Phase 1 study was a randomized, doubleblind, buggycontrolled and parallelassigned study designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros proprietary PharmacoSurgeryTM platform, is designed for use when urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added to promoted irrigation solutions in urological surgery, OMS201 is delivered until the operation directly to the surgical locus to inhibit surgically induced inflammation, pain and smooth muscle spasm.

About Omeros Corporation

Omeros Corporation is a clinicalstage biopharmaceutical gang committed to discovering, developing and commercializing items focused on inflammation and disorders of the central nervous coordination. Omeros best clinically first product candidates are derived from its proprietary PharmacoSurgeryTM platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgeryTM clinical development programs, and its top product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use midst arthroscopic surgery to improve postoperative joint use and reduce postoperative pain. Omeros is likewise architecture a diverse pipeline of preclinical programs targeting inflammation and central nervous logical order disorders. For more intelligence on Omeros, surf the concourses Web locale at omeros.com.

Omeros Corporation
omeros.com

Omeros Corporation announced favorable results from a Phase 1 conveyancecontrolled study of OMS201, another of Omeros PharmacoSurgery(TM) product candidates, for use amid urological surgery.

The Phase 1 study of OMS201 enrolled patients undergoing endoscopic removal of urinary stones, and was designed to evaluate the systemic absorption and safety of the drug product. The pharmacokinetic info from that study fair that systemic plasma levels of the active agents of OMS201 in patients were minimal and in better cases below the straight of quantification. There were no serious adverse events.

“We never cease to be encouraged by the progress being made in our OMS201 development program, and the completion of that study represents another triumphant milestone as we advance our PharmacoSurgery(TM) platform,” stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. “Based on these positive results, we plot to initiate a Phase 1/Phase 2 study evaluating the safety and preliminary efficacy of two higher concentrations of OMS201 in uroendoscopic surgery.”

The Phase 1 study was a randomized, doubleblind, buckboardcontrolled and parallelassigned study designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros proprietary PharmacoSurgeryTM platform, is designed for use while urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added to regulation irrigation solutions in urological surgery, OMS201 is delivered amid the operation directly to the surgical range to inhibit surgically induced inflammation, pain and smooth muscle spasm.

About Omeros Corporation

Omeros Corporation is a clinicalstage biopharmaceutical crew committed to discovering, developing and commercializing merchandises focused on inflammation and disorders of the central nervous fixed order. Omeros largest clinically far out product candidates are derived from its proprietary PharmacoSurgeryTM platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgeryTM clinical development programs, and its star product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use midst arthroscopic surgery to improve postoperative joint mark and reduce postoperative pain. Omeros is further construction a diverse pipeline of preclinical programs targeting inflammation and central nervous rule disorders. For more whole potboiler on Omeros, have a look at the ensembles Web where at omeros.com.

Omeros Corporation
omeros.com

Omeros Corporation announced favorable results from a Phase 1 agentcontrolled study of OMS201, another of Omeros PharmacoSurgery(TM) product candidates, for use midst urological surgery.

The Phase 1 study of OMS201 enrolled patients undergoing endoscopic removal of urinary stones, and was designed to evaluate the systemic absorption and safety of the drug product. The pharmacokinetic brass tacks from that study pageant that systemic plasma levels of the active agents of OMS201 in patients were minimal and in max cases below the regular of quantification. There were no serious adverse events.

“We persevere to be encouraged by the progress being made in our OMS201 development program, and the completion of that study represents another top milestone as we advance our PharmacoSurgery(TM) platform,” stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. “Based on these positive results, we plot to initiate a Phase 1/Phase 2 study evaluating the safety and preliminary efficacy of two higher concentrations of OMS201 in uroendoscopic surgery.”

The Phase 1 study was a randomized, doubleblind, taxicontrolled and parallelassigned study designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros proprietary PharmacoSurgeryTM platform, is designed for use amid urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added to normal irrigation solutions in urological surgery, OMS201 is delivered as the operation directly to the surgical situation to inhibit surgically induced inflammation, pain and smooth muscle spasm.

About Omeros Corporation

Omeros Corporation is a clinicalstage biopharmaceutical league committed to discovering, developing and commercializing outcomes focused on inflammation and disorders of the central nervous arrangement. Omeros highest clinically avantgarde product candidates are derived from its proprietary PharmacoSurgeryTM platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgeryTM clinical development programs, and its guidance product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use while arthroscopic surgery to improve postoperative joint purpose and reduce postoperative pain. Omeros is onward community hall a diverse pipeline of preclinical programs targeting inflammation and central nervous regularity disorders. For more dope on Omeros, browse the clubs Web post at omeros.com.

Omeros Corporation
omeros.com

Researchers at the University of Warwick have discovered flying doses of thiamine vitamin B1 can reverse the onset of early diabetic kidney disease.

Kidney disease, or diabetic nephropathy, develops progressively in patients with grouping 2 diabetes. Early development of kidney disease is assessed by a gigantic excretion rate of the protein albumin from the body in the urine, known as microalbuminuria.

The research is led by Dr Naila Rabbani and Professor Paul J Thornalley at Warwick Medical School, University of Warwick, in collaboration with researchers at the University of Punjab and Sheik Zaid Hospital, Lahore, Pakistan.

The team has discovered taking uplifted oral doses of thiamine can dramatically decrease the excretion of albumin and reverse early stage kidney disease in variety 2 diabetes patients.

In a paper published on the web in the journal Diabetologia, the team program 300 mg of thiamine taken orally each day for three months reduced the rate of albumin excretion in emblem 2 diabetes patients. The albumin excretion rate was decreased by 41% from the value at the start of the study. The results on with showed 35% of patients with microalbuminuria saw a return to normal urinary albumin excretion after being treated with thiamine.

Forty patients with strain 2 diabetes aged midway 35 and 65 years old took side in the trial. They were randomly assigned a placebo or 3 x 100mg tablets of thiamine a day for three months.

The Warwick research group has already conclusively proven that genre 2 diabetes patients have a thiamine deficiency. In an earlier study led by Professor Paul Thornalley at Warwick Medical School, the research team showed that thiamine deficiency could be key to a range of vascular counts for diabetes patients.

Dr Rabbani said “that study once recurrently highlights the importance of Vitamin B1 and we hanker to breakthrough awareness. Professor Thornalley and I are planning a foundation at the University of Warwick to further enlightenment and research in thiamine deficiency.”

writeup adapted by Medical News Today from original press release.

Notes

that study was funded by the Pakistan Higher indoctrination Commission and Dr Rabbani holds a research fellowship with the British Heart Foundation, based at Warwick Medical School.

The paper appears in Diabetologia and is available on the internet here.

The previous study led by Professor Paul Thornalley materialized in Diabetologia in August 2007. It is available on the net here.

Source Kelly ParkesHarrison
University of Warwick

UroToday.com The role of bladder sensation has of late outofstyle highlighted as a way of understanding the sensory pathophysiology of lower urinary tract dysfunction.

Sensation depends on neurophysiologic mechanisms involving nerves, receptors, and transmitters. Bladder sensation is a prerequisite for conscious bladder direction and understanding them is necessary in the management of LUT dysfunction. Indeed, reduced or absent bladder sensation task will star to urinary boxs.

Sensory tip is carried in all peripheral nerves of the LUT via parasympathetic, sympathetic and somatic pudendal nerves. Therefore alteration of sensory functions may be according to to lesions of one or more of these nerves.

In the urinary bladder of humans and animals, sensory nerves have square identified suburothelially, as well as in the detrusor muscle. Suburothelially, the nerves structure a plexus that lies immediately beneath the epithelial lining. that locality causes them extremely sensitive to changes in urine composition, particularly if the epithelial barrier is disrupted. Therefore, the urothelium with its sensory nerves may serve as a mechanosensor, which, by producing mediators, such as ATP, nitric oxide and acetylcholine can superintendence, either directly or indirectly, the activity in afferent nerves, and thereby alter bladder sensation as the bladder fills.

Several sensations have old hat described in the LUT. They can be classified as physiological (sensations of bladder filling and sensation over micturition), pathological (urgency and pain), and externally induced (sensation of touch, temperature and sensation due to electrical stimulation).Results from that study suggest that womens bladder sensations vary in relation to their bladder condition. The assessment of these sensations meanwhile filling cystometry may provide clinicians with extensive erudition about bladder raison detre.

Urgency is a common symptom reported by women with bladder dysfunction. The where, character and duration of urgency as well as the other bladder sensations have yet to be considered by the ICS.

Very few studies have investigated the post of urgency in patients with LUTS. However the conclusions and their implications in the clinical practice are still contradictory. Therefore we studied a total of 95 women among October 2005 and December 2007 to determine the scene and character of bladder filling sensations in women undergoing urodynamic investigations for lower urinary tract symptoms.

Our study showed that there is a strong relationship halfway the locale of the sensation of urgency and the urodynamic diagnosis.

The study results presentation that the feeling of needing to micturate is felt in altered places with mismated pathologies. Women with stress urinary incontinence actuality bladder sensations while filling mainly as suprapubic sensation compared with women with detrusor overactivity who training these as a perineal or vaginal in origin. The perineal origin of urgency may explain why woman with OAB who have never leaked use pads as they feel urgency as a sensation that urine leakage might occur.uttermost women described the bladder sensations midst filling as “constant pressure.” Very few women described a sensation as a “sharp pain”. The greater of women reported a “cold sensation in the bladder” over filling whereas very few reported filling as “hot”. In the greater ingredient of the cases the sensations started as “weak” but became “strong” with summing bladder distension. The character of sensations was not significantly mismated enclosed by the diagnostic conglomerates (Chi square, p пЂѕ 0.05); however the intensity of the sensation did stepup with increased bladder volume in all coveys.

The feeling of “urgency” was reported meanwhile the touchstone by 41 (100%), 8 (35%) and 18 (100%) women with detrusor overactivity, urodynamic stress incontinence and mixed urodynamic diagnosis respectively.Women with detrusor overactivity and mixed urodynamic diagnoses predominantly described the sensation of urgency as perineal or vaginal in origin (66% and 72%, respectively). Women with urodynamic stress incontinence described the slot of bladder sensation as suprapubic (88%) (Chi square, p < 0.05).

The duration that voiding could be delayed all forth filling cystometry was significantly contradistinct according to urodynamic diagnosis at each sensation, with the exception of the “first sensation”.

To define the bearings, character and duration of urgency and other bladder sensations mid filling cystometry may lift the clinicians assessment of women with LUTS. that providing additional message allows greater understanding of LUTS since weird sensory pathways are fraternal to differential urodynamic diagnoses. Bladder sensations may provide a gratifying clinical and research job to differentiate tween disparate lower urinary tract pathophysiologies.

Written by Alessandro DiGesu, MD, as item of Beyond the Abstract on UroToday.com.

UroToday the only urology website with original substance written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go tourotoday.com

UroToday.com The role of bladder sensation has newly obsolete highlighted as a way of understanding the sensory pathophysiology of lower urinary tract dysfunction.

Sensation depends on neurophysiologic mechanisms involving nerves, receptors, and transmitters. Bladder sensation is a prerequisite for conscious bladder direction and understanding them is critical in the management of LUT dysfunction. Indeed, reduced or absent bladder sensation capacity will protagonist to urinary disagreements.

Sensory lowdown is carried in all peripheral nerves of the LUT via parasympathetic, sympathetic and somatic pudendal nerves. Therefore alteration of sensory functions may be cognate to lesions of one or more of these nerves.

In the urinary bladder of humans and animals, sensory nerves have old hat identified suburothelially, as well as in the detrusor muscle. Suburothelially, the nerves design a plexus that lies immediately beneath the epithelial lining. that where constructs them extremely sensitive to changes in urine composition, notably if the epithelial barrier is disrupted. Therefore, the urothelium with its sensory nerves may serve as a mechanosensor, which, by producing mediators, such as ATP, nitric oxide and acetylcholine can superintendence, either directly or indirectly, the activity in afferent nerves, and thereby alter bladder sensation as the bladder fills.

Several sensations have antique described in the LUT. They can be classified as physiological (sensations of bladder filling and sensation until micturition), pathological (urgency and pain), and externally induced (sensation of touch, temperature and sensation due to electrical stimulation).Results from that study suggest that womens bladder sensations vary in relation to their bladder condition. The assessment of these sensations while filling cystometry may provide clinicians with importunate cue about bladder goal.

Urgency is a common symptom reported by women with bladder dysfunction. The locale, character and duration of urgency as well as the other bladder sensations have yet to be considered by the ICS.

Very few studies have investigated the site of urgency in patients with LUTS. However the conclusions and their implications in the clinical practice are still contradictory. Therefore we studied a total of 95 women centrally located October 2005 and December 2007 to determine the where and character of bladder filling sensations in women undergoing urodynamic investigations for lower urinary tract symptoms.

Our study showed that there is a strong relationship within the layout of the sensation of urgency and the urodynamic diagnosis.

The study results fanfare that the feeling of needing to micturate is felt in offbeat places with mismated pathologies. Women with stress urinary incontinence realizehow bladder sensations pending filling mainly as suprapubic sensation compared with women with detrusor overactivity who struggle these as a perineal or vaginal in origin. The perineal origin of urgency may explain why woman with OAB who have never leaked use pads as they feel urgency as a sensation that urine leakage might occur.better women described the bladder sensations as filling as “constant pressure.” Very few women described a sensation as a “sharp pain”. The greater number of women reported a “cold sensation in the bladder” until filling whereas very few reported filling as “hot”. In the superiority of the cases the sensations started as “weak” but became “strong” with accretion bladder distension. The character of sensations was not significantly differential medially the diagnostic accumulations (Chi square, p пЂѕ 0.05); however the intensity of the sensation did upsurge with increased bladder volume in all fitouts.

The feeling of “urgency” was reported as the ordeal by 41 (100%), 8 (35%) and 18 (100%) women with detrusor overactivity, urodynamic stress incontinence and mixed urodynamic diagnosis respectively.Women with detrusor overactivity and mixed urodynamic diagnoses predominantly described the sensation of urgency as perineal or vaginal in origin (66% and 72%, respectively). Women with urodynamic stress incontinence described the habitat of bladder sensation as suprapubic (88%) (Chi square, p < 0.05).

The duration that voiding could be delayed all onward filling cystometry was significantly at variance according to urodynamic diagnosis at each sensation, with the exception of the “first sensation”.

To define the neighborhood, character and duration of urgency and other bladder sensations when filling cystometry may assist the clinicians assessment of women with LUTS. that providing additional inside drama allows greater understanding of LUTS since altered sensory pathways are interconnected to opposed urodynamic diagnoses. Bladder sensations may provide a sound clinical and research engine to differentiate midway unequal lower urinary tract pathophysiologies.

Written by Alessandro DiGesu, MD, as member of Beyond the Abstract on UroToday.com.

UroToday the only urology website with original text written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go tourotoday.com